Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMuñoz de Nova, Jose Luis
dc.contributor.authorHernando Cubero, Jorge
dc.contributor.authorSampedro-Núñez, Miguel
dc.contributor.authorVázquez Benítez, Greissy Tibisay
dc.contributor.authorTriviño-Ibañez, Eva-Maria
dc.contributor.authorDel Olmo García, Maria Isabel
dc.contributor.authorBarriuso, J.
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorMartin-Perez, Elena
dc.date.accessioned2022-09-08T11:36:43Z
dc.date.available2022-09-08T11:36:43Z
dc.date.issued2022-04-07
dc.identifier.citationMuñoz de Nova JL, Hernando J, Sampedro Núñez M, Vázquez Benítez GT, Triviño Ibáñez EM, Del Olmo García MI, et al. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy. World J Gastroenterol. 2022 Apr 7;28(13):1304–14.
dc.identifier.issn2219-2840
dc.identifier.urihttp://hdl.handle.net/11351/8075
dc.descriptionAppendiceal neoplasms; Carcinoid tumor; Treatment outcome
dc.description.abstractAppendiceal neuroendocrine tumors (aNETs) are an uncommon neoplasm that is relatively indolent in most cases. They are typically diagnosed in younger patients than other neuroendocrine tumors and are often an incidental finding after an appendectomy. Although there are numerous clinical practice guidelines on management of aNETs, there is continues to be a dearth of evidence on optimal treatment. Management of these tumors is stratified according to risk of locoregional and distant metastasis. However, there is a lack of consensus regarding tumors that measure 1-2 cm. In these cases, some histopathological features such as size, tumor grade, presence of lymphovascular invasion, or mesoappendix infiltration must also be considered. Computed tomography or magnetic resonance imaging scans are recommended for evaluating the presence of additional disease, except in the case of tumors smaller than 1 cm without additional risk factors. Somatostatin receptor scintigraphy or positron emission tomography with computed tomography should be considered in cases with suspected residual or distant disease. The main point of controversy is the indication for performing a completion right hemicolectomy after an initial appendectomy, based on the risk of lymph node metastases. The main factor considered is tumor size and 2 cm is the most common threshold for indicating a colectomy. Other factors such as mesoappendix infiltration, lymphovascular invasion, or tumor grade may also be considered. On the other hand, potential complications, and decreased quality of life after a hemicolectomy as well as the lack of evidence on benefits in terms of survival must be taken into consideration. In this review, we present data regarding the current indications, outcomes, and benefits of a colectomy.
dc.language.isoeng
dc.publisherBaishideng Publishing Group
dc.relation.ispartofseriesWorld journal of gastroenterology;28(13)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectApendicectomia
dc.subjectTumors neuroendocrins - Diagnòstic
dc.subjectApèndix (Anatomia) - Càncer
dc.subject.meshNeuroendocrine Tumors
dc.subject.mesh/diagnosis
dc.subject.meshAppendectomy
dc.subject.meshAppendiceal Neoplasms
dc.titleManagement of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3748/wjg.v28.i13.1304
dc.subject.decstumores neuroendocrinos
dc.subject.decs/diagnóstico
dc.subject.decsapendicectomía
dc.subject.decsneoplasias del apéndice
dc.relation.publishversionhttp://dx.doi.org/10.3748/wjg.v28.i13.1304
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Muñoz de Nova JL, Martín-Pérez E] Department of General and Digestive Surgery, Hospital Universitario de La Princesa, Madrid 28006, Spain. Department of Surgery, Universidad Autónoma de Madrid, Madrid 28029, Spain. [Hernando J, Capdevila J] Tumors Gastrointestinals i Endocrins, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sampedro Núñez M] Department of Endocrinology and Nutrition, Hospital Universitario de La Princesa, Madrid 28006, Spain. [Vázquez Benítez GT] Department of Pathology, Hospital Universitario Puerta de Hierro, Madrid 28222, Spain. Department of Pathology, Universidad Autónoma de Madrid, Madrid 28029, Spain. [Triviño Ibáñez EM] Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Granada 18014, Spain. [Del Olmo García MI] Department of Endocrinology and Nutrition, Hospital Universitario i Politècnic La Fe, Valencia 46023, Spain. [Barriuso J] Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom
dc.identifier.pmid35645544
dc.identifier.wos000797337500002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record